Beacon Equity Research: Anadys (ANDS) Skyrockets on Acquisition by Roche Holdings
Shares of Anadys Pharmaceuticals Inc., a biopharmaceutical company engaged in the development of medicines for the treatment of hepatitis C, are seeing a huge rally in today’s trading after the company agreed to be acquired by Roche Holdings AG. At last check, Anadys Pharmaceuticals shares were trading 250.96% higher at $3.65, with volume up from daily average of 431,946. Switzerland-based Roche agreed to acquire Anadys for $230 million in cash. The acquisition will boost Roche’s hepatitis franchise and broaden its business outside cancer medicine operations. Under the terms of agreement between the two companies, Roche will pay $3.70 per share…